顶体反应抑制剂4'- 乙酰胺苯基4-胍基苯甲酸酯(AGB)具有阻断HIV-1进入细胞的作用

】目的: 研究4'- 乙酰胺苯基4- 胍基苯甲酸酯(AGB)抗 HIV-1 活性及作用靶点。方法: 通过 AGB对宿主细胞的毒性实验、合胞体抑制实验、融合阻断实验、对HIV-1感染细胞的保护作用实 验和对HIV-1急性感染细胞p24抗原产生的抑制作用等试验，观察AGB对HIV-1复制的影响和作 关键词: AGB; HIV-1; 病毒进入; 杀微生物剂; 杀精子活性 中图分类号: R967; 文献标识码: A 文章编号: 0253-357X(2005)11-0660-05 本研究为国家高技术研究发展计划(2003AA219142)、国 家科技攻关计划 (2004BA719A14)、中国科学院知识创新 工程重要方向(KSCX2-SW-216; KSCX12-SW-11)、云南 省科技攻关计划(2004NG12)和云南省生育调节与少数民 族优生研究重点实验室资助项目 通讯作者: 郑永唐; Tel: +86-871-5195684; Fax:+86-871-5191823; E-mail: zhengyt@mail.kiz.ac.cn 在我国, 人免疫缺陷病毒(human immunodeficiency virus, HIV)危害日趋严重，处在全国低流行 与局部地区及特定人群高流行并存的态势。卫生部 的数据显示，截止2005 年3 月底，全国累计报告 HIV 感染者114 703 例。专家估计我国实际HIV 感 染者超过100 万人。预计到2010 年, 全国HIV感染 者将突破千万。截止2004 年底, 云南省累计报告的 HIV 感染者已达28 391 人, 是全国流行最严重的地 区。艾滋病流行正由高危人群向一般人群传播。 新的证据显示近年来由性传播途径感染的比例有所 上升, 女性感染者的比例有较大幅度的上升, 迫切需 要发展一种女性可自主控制的方法 [1]。杀微生物剂 是可以局部用药于阴道和宫颈、能够杀灭或抑制 包括HIV等病毒性和细菌性病原体、人工合成或天 然的药物。具有避孕作用的杀微生物剂更是近年 来的研究热点，也具有广阔的应用前景[2,3]。 顶体酶是存在于精子顶体内的一种类胰蛋白 酶, 它是受精过程中的一种重要的蛋白水解酶, 此酶 能水解卵细胞的透明带, 使精子能够与卵细胞相融 合; 顶体酶还能促进生殖系统中激肽的释放, 后者能 够增强精子的活力和促进精子的运动, 顶体酶的失 活将导致不孕[4]。AGB(4'- 乙酰胺苯基 4- 胍基苯甲 酸酯)是顶体酶的抑制剂, 实验表明在多种动物中有 很好的杀精子作用[5-7]。Bourimbaiar等[8]曾报道AGB 还具有体外抗HIV-1的作用, 活性较N-9高, 且毒性 较小。在本实验中, 我们发现AGB 的体外抗HIV-1 活性主要是阻断HIV-1 进入细胞。 用机制。结果: AGB抑制HIV-1IIIB诱导C8166细胞形成合胞体, EC50为39.5 μg/ml; 抑制HIV-1感染 细胞上清中HIV-1 p24抗原的表达, EC50为33.36 μg/ml; 阻断HIV-1慢性感染H9细胞与正常C8166 细胞间融合的作用。结论: AGB具有阻断HIV-1 进入宿主细胞的作用，是一种有前景的具杀精子 作用的杀微生物剂。

天然产物中的HIV-1 非核苷类逆转录酶抑制剂

综述了天然产物中对H IV 21 逆转录酶具有抑制活性的化合物的来源和分类。重点介绍了几种H IV 21 非核 苷类逆转录酶抑制剂(NNRT Is) 的性质、特点、抗H IV 21 活性及其构效关系。从天然资源和传统中草药发现具有新 结构、新作用机制的天然NNRT Is 是开发研制抗H IV 21 药物的一条极有希望的途径。

脂质体携载抗HIV-1药物

由于mV耐药株的产生、特殊器官和细胞中}Ⅱv的隐匿、抗}Ⅱv药物的毒副反应及半衰期短等问题的出现．促 使人们寻找高效低毒和具有靶向性的抗Ⅲv药物。脂质体具有被动或主动靶向病毒复制活跃和贮存区、细胞内靶向和控制药 物释放、延长药物半衰期、提高药效和降低毒副作用等优点．是潜在携载抗}Ⅱv药物的良好载体。

17种植物中蛋白质提取物的抗HIV-1活性

以化合物对ＨＩＶ１诱导Ｃ８１６６细胞形成合胞体的抑制实验和化合物对ＨＩＶ１感染细胞的保护实验作为初筛方法，筛选了来源于７科１７种植物的４７个样品，其中８个样品经测定是核糖体失活蛋白（ＲＩＰｓ），其余为粗提蛋白。进而测定了初筛有抗ＨＩＶ活性的化合物对共培养、急性和慢性感染的ＨＩＶ１ｐ２４抗原表达水平的影响，用间接荧光染色检测这些化合物对ＨＩＶ抗原阳性细胞率的影响，以确证其抗ＨＩＶ活性。天花粉蛋白（ＴＣＳ）、南方栝楼蛋白峰Ⅴ、南方栝楼蛋白峰Ⅵ均显著地抑制合胞体的形成；巴Ⅱ、丝瓜子蛋白、油瓜根蛋白、木盍藤子蛋白有一定的抑制作用。老鼠拖瓜蛋白、大叶木鳖子根蛋白、西双版纳根Ⅱ等粗提蛋白有显著的抑制作用。ＲＩＰｓ不能保护ＨＩＶ１感染细胞的死亡。ＴＣＳ显著地抑制了ＨＩＶ１急性感染中ｐ２４抗原的表达，减少了ＨＩＶ抗原阳性细胞数，但它们均不影响共培养细胞融合、ＨＩＶ１慢性感染中ｐ２４抗原表达水平。结果表明，除ＴＣＳ等已知ＲＩＰｓ外，还有一些新的ＲＩＰｓ具有不同程度的抗ＨＩＶ活性。

HIV-1慢性感染Jurkat细胞系的建立及其特性研究

目的　建立艾滋病病毒Ⅰ型( HIV21) 慢性感染J urkat 细胞系,研究其生物学特性。方法　参照文献方法改良,建立HIV21 ⅢB慢性感染J urkat 细胞系。其细胞系特性采用以下方法检测:光学显微镜观察细胞形态;流式细胞仪检测HIV21 ⅢB感染细胞的阳性率;噻唑蓝(MTT) 法检测抗病毒药物对慢性感染细胞的毒性作用;酶联免疫吸附试验( EL ISA) 检测药物对慢性感染细胞中病毒复制的影响;合胞体形成方法检测药物对HIV21 ⅢB慢性感染细胞与正常细胞融合的阻断作用。结果　成功建立了HIV21 慢性感染J urkat 细胞系(J urkat/ HIV21 ⅢB ) ,感染细胞阳性率> 90 %。检测影响病毒复制各周期的抗病毒药物对J urkat/ HIV21 ⅢB细胞的作用,发现J urkat/ HIV21 ⅢB细胞具有 HIV21 慢性感染细胞的生物学特征。结论　成功建立J urkat/ HIV21 ⅢB 细胞系,为抗HIV21 药物的研发和病毒感染机制研究提供了新的工具。

云南省HIV-1分子流行病学研究进展

云南省是中国HIV-1感染最早和最为严重的地区之一,流行的HIV-1病毒亚型种类复杂多样。已有证据表明国内其它地区的HIV-1亚型很可能主要来源于云南省。本文对云南省的HIV-1亚型的流行情况进行综述,希望能为预防控制云南省乃至全国HIV-1的流行以及合理设计HIV-1疫苗提供基础信息。

半乳糖神经酰胺脂质体对HIV-1感染性的影响

目的研究体外空白及包封抗HIV药物和PFA的GalCer脂质体对HIV-1复制的影响。方法通过HIV p24抗原测定、合胞体抑制实验、融合阻断实验和对HIV感染细胞的保护作用实验等，观察了空白GalCer脂质体、AZT-GalCer脂质体和PFA-GalCer脂质体对HIV-1复制的影响。结果空白GalCer脂质体预处理细胞，能促进HIV-1感染CD4＋细胞；空白GalCer脂质体预处理HIV-1，则抑制了病毒吸附和结合宿主细胞；GalCer脂质体还具有阻断HIV-1感染细胞与正常CD4＋细胞间的融合作用；GalCer脂质体包封AZT或PFA不能显著提高药物体外抗HIV-1活性。结论空白GalCer脂质体预处理细胞，能促进HIV-1感染性；预处理HIV-1，则抑制了病毒的感染。

非核苷类逆转录酶抑制剂在抗HIV-1中的作用

非核苷类RT抑制剂是一大类化学结构各异的化合物,它们结合于RT上一个非底物结合的变构部位,使RT失去活性。从天然化合物中寻找新的非核苷类RT抑制剂是一条治疗HIV-1感染的极有希望的途径。

Anti-HIV-1 activity of trichobitacin, a novel ribosome-inactivating protein

AIM: To determine whether trichobitacin, a novel ribosome-inactivating protein purified from the root tubers of Trichosanthes kirilowii, possesses the anti-HIV activity. METHODS: The inhibition of syncytial cell formation induced by human immunodeficiency virus type 1 (HIV-1),was determined under microscope, reduction of HIV-1 p24 antigen expression level was measured by ELISA, and decrease in numbers of HIV-1 antigen positive cells in acutely and-chronically infected cultures were detected by indirect immunofluorescence assay. RESULTS: Trichobitacin Was-found to greatly suppress syncytial cell formation induced by HIV-1 and to markedly reduce both expression of HIV-1 p24 antigen and the number of HIV antigen positive cells in acutely but not chronically HIV-1 infected culture. The median inhibitory concentration (IC50) in inhibition of syncytial cell formation and HIV antigen positive cells were 5 mu g.L-1 (95 % confidence limits: 1.3 - 20 mu g.L-1) and 0.09 mg.L-1 (95 % confidence limits: 0.011 - 0.755 mg.L-1), respectively. CONCLUSION: Trichobitacin is a novel ribosome-inactivating protein with anti-HIV-l activity.

Anti-HIV-1 property of trichosanthin correlates with its ribosome inactivating activity

Trichosanthin (TCS) is a type I ribosome inactivating (RI) protein possessing anti-tumor and antiviral activity, including human immunodeficiency virus (HIV). The mechanism of these actions is not entirely clear, but is generally attributed to its RI property. In order to study the relationship between the anti-HIV-1 activity of TCS and its RI activity, three TCS mutants with different RI activities were constructed by using site-directed mutagenesis. The anti-HIV-1 activities of the three mutants were tested in vitro. Results showed that two TCS mutants, namely TCSM((120-123)), TCSE160A/E189A, with the greatest decrease in RI activity, lost almost all of the anti-HIV activity and cytopathic effect. Another mutant TCSR122G, which exhibited a 160-fold decrease in RI activity, retained some anti-HIV activity. The results from this study suggested that RI activity of TCS may have significant contribution to its anti-HIV-1 property. (C) 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.

Independency of anti-HIV-1 activity from ribosome-inactivating activity of trichosanthin

Trichosanthin (TCS) is a type I ribosome-inactivating (RI) protein possessing multiple biological and pharmacological activities. Its major action is inhibition of human immunodeficiency virus (HIV) replication but the mechanism is still elusive. All evidences showed that this action is related to its RI activity. Previous studies found that TCS mutants with reduced RI activity simultaneously lost some anti-HIV activity. In this study, an exception was demonstrated by two TCS mutants retaining almost all RI activity but were devoid of anti-HIV-1 activity. Five mutants were constructed by using site-directed mutagenesis with either deletion or addition of amino acids to the C-terminal sequence. Results showed that the RI activity of mutants with C-terminal deletion mutants (TCSC2, TCSC4, and TCSC14) decreased by 1.2-3.3-fold with parallel downshifting of its anti-HIV-1 activity (1.4-4.8-fold). Another two mutants, TCSC19aa and TCSKDEL having 19 amino acid extension and a KDEL signal sequence added to the C-terminal sequence, retained all RI activity but subsequently lost most of the anti-HIV-1 activity. These findings suggested that ribosome inactivation alone might not be adequate to explain the anti-HIV action of TCS. (C) 2003 Elsevier Science (USA). All rights reserved.

Xanthohumol, a novel anti-HIV-1 agent purified from Hops Humulus lupulus

Xanthohumol, prenylchacone flavonoid, is a natural product with multi-biofunctions purified from Hops Humulus lupulus. Its anti-HIV-1 activity was tested in the present study. Results showed that xanthohumol inhibited HIV-1 induced cytopathic effects, the production of viral p24 antigen and reverse transcriptase in C8166 lymphocytes at non-cytotoxic concentration. The EC50 values were 0.82, 1.28 and 0.50 mug/ml, respectively. The therapeutic index (TI) was about 10.8. Xanthohumol also inhibited HIV-1 replication in PBMC with EC50 value of 20.74 mug/ml. The activity of recombinant HIV-1 reverse transcriptase and the HIV-1 entry were not inhibited by xanthohumol. The results from this study suggested that xanthohumol is effective against HIV-1 and might serve as an interesting lead compound. It may represent a novel chemotherapeutic agent for HIV-1 infection. However, the mechanism of its anti-HIV-1 effect needs to be further clarified. (C) 2004 Elsevier B.V. All rights reserved.

Zinc coupling potentiates anti-HIV-1 activity of baicalin

Baicalin (BA) has been shown with anti-HIV-1 activity. Zinc is a nutrient element. The anti-HIV-1 activity of zinc complex of baicalin (BA-Zn) in vitro was studied and compared with the anti-HIV-1 activities between BA and BA-Zn in the present study. Our results suggested that BA-Zn has lower cytotoxicity and higher anti-HIV-1 activity compared with those of BA in vitro. The CC(50)s of BA-Zn and BA were 221.52 and 101.73 muM, respectively. The cytotoxicity of BA-Zn was about 1.2-fold lower than that of BA. The BA and BA-Zn inhibited HIV-1 induced syncytium formation, HIV-1 p24 antigen and HIV-1 RT production. The EC(50)s of BA-Zn on inhibiting HIV-1 induced syncytium formation (29.08 muM) and RT production (31.17 muM) were lower than those of BA (43.27 and 47.34 muM, respectively). BA-Zn was more effective than BA in inhibiting the activities of recombinant RT and HIV-1 entry into host cells. Zinc coupling enhanced the anti-HTV-1 activity of baicalin. (C) 2004 Elsevier Inc. All rights reserved.

Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro

Aim: To study the pharmacokinetics of sifuvirtide, a novel anti-human immunodeficiency virus (HIV) peptide, in monkeys and to compare the inhibitory concentrations of sifuvirtide and enfuvirtide on HIV-1-infected-cell fusion. Methods: Monkeys received 1.2 mg/kg iv or sc of sifuvirtide. An on-line solid-phase extraction procedure combined with liquid chromatography tandem mass spectrometry (SPELC/MS/MS) was established and applied to determine the concentration of sifuvirtide in monkey plasma. A four-I-127 iodinated peptide was used as an internal standard. Fifty percent inhibitory concentration (IC50) of sifuvirtide on cell fusion was determined by co-cultivation assay. Results: The assay was validated with good precision and accuracy. The calibration curve for sifuvirtide in plasma was linear over a range of 4.88-5000 mu g/L, with correlation coefficients above 0.9923. After iv or sc administration, the observed peak concentrations of sifuvirtide were 10626 +/- 2886 mu g/L and 528 +/- 191 mu g/L, and the terminal elimination half-lives (T,12) were 6.3 +/- 0.9 h and 5.5 +/- 1.0 h, respectively. After sc, T-max was 0.25-2 h, and the absolute bioavailability was 49% +/- 13%. Sifuvirtide inhibited the syncytium formation between HIV-1 chronically infected cells and uninfected cells with an IC50 of 0.33 mu g/L. Conclusion: An on-line SPE-LC/MS/MS approach was established for peptide pharmacokinetic studies. Sifuvirtide was rapidly absorbed subcutaneously into the blood circulation. The T-1/2 of sifuvirtide was remarkably longer than that of its analog, enfuvirtide, reported in healthy monkeys and it conferred a long-term plasma concentration level which was higher than its IC50 in vitro.

The anti-HIV-1 effect of scutellarin

Scutellarin was purified from the plant Erigeron breuiscapus (Vant.) Hand.-Mazz. The activity against 3 strains of human immunodeficiency virus (HIV) was determined in vitro in this study. These were laboratory-derived virus (HIV-I-IIIB), drug-resistant virus (HIV-I-74V), and low-passage clinical isolated virus (HIV-1(KM018)). From syncytia inhibition study, the EC50 of scutellarin against HIV-I-IIB direct infection in C8166 cells was 26 mu M with a therapeutic index of 36. When the mode of infection changed from acute infection to cell-to-cell infection, this compound became even more potent and the EC50 reduced to 15 mu M. This suggested that cell fusion might be affected by this compound. By comparing the inhibitory effects on p24 antigen, scutellarin was also found to be active against HIV-1(74V) (EC50 253 mu M) and HIV-1(KM018) (EC50 136 mu M) infection with significant difference in potency. The mechanism of its action was also explored in this study. At a concentration of 433 mu M, scutellarin inhibited 48% of the cell free recombinant HIV-1 RT activity. It also caused 82% inhibition of HIV-1 particle attachment and 45% inhibition of fusion at the concentrations of 54 mu M. In summary, scutellarin was found to inhibit several strains of HIV-1 replication with different potencies. It appeared to inhibit HIV-1 RT activity, HIV-1 particle attachment and cell fusion. These are essential activities for viral transmission and replication. (c) 2005 Elsevier Inc. All rights reserved.